Several states (e.g., North Carolina, California, Connecticut, Rhode Island, Michigan) have paused or proposed ending Medicaid coverage for GLP1 drugs for weight loss due to escalating costs, while continuing coverage for diabetes or cardiovascular risk indications
Many Medicare contractors prefer RT/LT for bilateral claims instead of modifier 50, so payer policy review is required
You can head to our cost comparison tool for more detailed information on the cost of GLP-1 weight-loss medications
elegans strains and maintenance C
Hope youll subscribe to this newsletter, and please hit the "like" button
The moment its FDA-approved and available, well integrate retatrutide into our offerings likely as a premium option for those who need that next level of efficacy